Novartis' Ultibro Breezhaler better at reducing COPD flare-ups than GSK's Seretide, study shows

3 September 2016
novartis-big

A comparative study has suggested that Swiss pharma major Novartis’ (NOVN: GSK) Ultibro Breezhaler (indacaterol/glycopyrronium bromide) is consistently a more effective option than its rival from GlaxoSmithKline (LSE: GSK) for patients at risk of chronic obstructive pulmonary disease (COPD) flare-ups.

The findings from the FLAME study, comparing the Ultibro Breezhaler with the UK pharma major’s Seretide (salmeterol/fluticasone propionate) across different patient sub-groups, are being presented at the European Respiratory Society (ERS) International Congress this week.

Once-daily Ultibro Breezhaler 110/50mcg demonstrated consistent reductions in all exacerbations regardless of age, smoking status, exacerbation history, disease severity, eosinophil levels and previous inhaled corticosteroid (ICS) use, versus twice-daily Seretide 50/500mcg.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical